The congress of European Society of Toxicology In Vitro (ESTIV) took place from 21st to 25th November 2022. This congress is focus on the alternative methods to animal testing, including both in silico and in vitro modeling. After a nice opening ceremony with a flamenco show, the scientific program begun Read more…
Our Project Leader in in vitro pharmacology Méryl Roudaut will present his presentation entitled “A single procedure to generate functional hiPSCs-derived liver organoids – Towards an innovative tools suitable for drug screening” during the session: Early Stage Researcher Session I (Tuesday, November 22nd, 2022). Abstract #165: We previously showed that Read more…
Hepatotoxicity testing in animals predicts only 50% of liver damage observed in clinical context, in part, because of difference in inter-species hepatic metabolism (1). Therefore, a relevant in vitro model mimicking the micro-environment of the human liver for maintaining and promoting hepatocyte functions, is needed for a better hepatotoxicity prediction Read more…
Many categories of drugs can induce hepatotoxicity, so improving the prediction of toxic drugs is important. In vitro models using human hepatocytes are more accurate than in vivo animal models. Good in vitro models require an abundance of metabolic enzyme activities and normal cellular polarity. However, none of the in Read more…
HCS/HCA is a great way to predict drugs toxicity
I was present at the last congress ELRIGfr in Brussels. It was a strong exchange place with interesting presentations around robotics. It is always really interesting to see examples of innovative automation which give really robust results.